dabigatran
Trade name: pradaxa
Small moleculeapproved
Approved
Oct 19, 2010
Dabigatran ethyl ester is a one of the intermediate, which is formed during metabolic reactions from dabigatran etexilate. Dabigatran ethyl ester forming under the action of intestinal carboxylesterase 2 (CES2) further is hydrolyzed by CES1 with formation of active drug, thrombin inhibitor, dabigatranand. Dabigatran ethyl ester is a much stronger inhibitor of ribosyldihydronicotinamide dehydrogenase, than dabigatran. — NCATS
Clinical trial activity
225 trials · 175 clinical orgs · 12 marketing orgs
Phase 1
97
Phase 2
54
Phase 3
36
Phase 4
51
Earliest trial started Nov 1, 1998 (NCT02170116)
Timeline
1990s
- Jan 1, 1998
Boehringer Ingelheim — Earliest Phase 1 Sponsor(trial)
2000s
- Jan 1, 2000
Boehringer Ingelheim — Earliest Phase 2 Sponsor(trial)
- Jan 1, 2004
Boehringer Ingelheim — Earliest Phase 3 Sponsor(trial)
2010s
- Oct 19, 2010
Boehringer Ingelheim — Earliest FDA Approval
- Oct 19, 2010
Boehringer Ingelheim — NDA Secondary Org
- Oct 19, 2010
Boehringer Ingelheim — NDA Organization
- Apr 18, 2017
Glenmark Pharmaceuticals — Marketing Organization
- Apr 19, 2017
Teva — Marketing Organization
- Jul 7, 2017
Alembic — Marketing Organization
2020s
- Mar 11, 2020
Alkem Labs Ltd — Marketing Organization
- May 6, 2020
Hetero Labs Ltd — Marketing Organization
- Oct 26, 2020
Dr. Reddy's Laboratories — Marketing Organization
- Jan 21, 2022
Mylan — Marketing Organization
- Mar 21, 2022
Esteve Labs — Marketing Organization
- Mar 21, 2022
MSN Laboratories — Marketing Organization
- Dec 15, 2023
Apotex — Marketing Organization
- May 14, 2025
Aurobindo Pharma — Marketing Organization
Indications
Studied for
- Acute Coronary Syndrome · Phase 4
- Alzheimer Disease · Phase 1
- Aneurysm · Phase 3
- Angina, Stable · Phase 4
- Angina, Unstable · Phase 4
- Anticoagulants · Phase 4
- Antithrombins · Phase 4
- Aortic Valve Disease · Phase 4
- Aortic Valve Stenosis · Phase 4
- Appendix · Phase 4
- Arthroplasty, Replacement · Phase 4
- Arthroplasty, Replacement, Hip · Phase 3
- Arthroplasty, Replacement, Knee · Phase 3
- Atherosclerosis · Phase 4
- Atrial Fibrillation · Phase 4
- Atrial Flutter · Phase 4
- Blood Coagulation Disorders · Phase 1
- CADASIL · Phase 2
- Carcinoma, Non-Small-Cell Lung · Phase 1
- Cardiac Catheterization · Phase 2
- Cardiovascular Diseases · Phase 1
- Cerebral Hemorrhage · Phase 3
- Cerebral Intraventricular Hemorrhage · Phase 3
- Cerebrovascular Disorders · Phase 3
- Cognition Disorders · Phase 4
- Cognitive Dysfunction · Phase 1
- Colorectal Neoplasms · Phase 1
- Coronary Artery Disease · Phase 4
- Coronary Disease · Phase 4
- Cough · Phase 1
- COVID-19 · Phase 1
- Cushing Syndrome · Phase 1
- Dabigatran · Phase 1
- Dementia · Phase 4
- Dermatitis, Atopic · Phase 1
- Diabetes Mellitus · Phase 4
- Diabetes Mellitus, Type 2 · Phase 4
- Drug Interactions · Phase 1
- Drugs, Generic · Phase 1
- Drugs, Investigational · Phase 3
- Electric Countershock · Phase 3
- Erb-b2 Receptor Tyrosine Kinases · Phase 1
- Foramen Ovale, Patent · Phase 3
- General Surgery · Phase 3
- Healthy Volunteers · Phase 2/Phase 3
- Heart Diseases · Phase 4
- Heart Valve Diseases · Phase 4
- Heart Valve Prosthesis · Phase 2
- Hematoma · Phase 3
- Hematoma, Subdural · Phase 3
- Hemorrhage · Phase 4
- Hepatic Insufficiency · Phase 1
- Hot Flashes · Phase 1
- Hypertrophy, Left Ventricular · Phase 4
- Intracranial Hemorrhage, Hypertensive · Phase 3
- Intracranial Hemorrhages · Phase 3
- Ischemia · Phase 4
- Ischemic Attack, Transient · Phase 4
- Ischemic Stroke · Phase 4
- Kidney Diseases · Phase 4
- Kidney Failure, Chronic · Phase 1
- Liver Cirrhosis · Phase 2/Phase 3
- Lung Diseases, Interstitial · Phase 1
- Migraine Disorders · Phase 3
- Mitral Valve Stenosis · Phase 4
- Mutation · Phase 1
- Myocardial Infarction · Phase 4
- Myocardial Ischemia · Phase 4
- Neoplasms · Phase 1
- Non-ST Elevated Myocardial Infarction · Phase 4
- Pancreatitis · Phase 1
- Percutaneous Coronary Intervention · Phase 4
- Pharmacokinetics · Phase 1
- Prostatic Neoplasms · Phase 1
- Pulmonary Embolism · Phase 4
- Renal Insufficiency · Phase 1
- Renal Insufficiency, Chronic · Phase 4
- Respiratory Syncytial Virus Infections · Phase 1
- Scleroderma, Systemic · Phase 1
- Secondary Prevention · Phase 3
- Staphylococcal Infections · Phase 4
- Staphylococcus aureus · Phase 4
- ST Elevation Myocardial Infarction · Phase 4
- Stroke · Phase 4
- Subarachnoid Hemorrhage · Phase 3
- Thromboembolism · Phase 4
- Thrombosis · Phase 4
- Vascular Diseases · Phase 4
- Vasomotor System · Phase 1
- Venous Thromboembolism · Phase 4
- Venous Thrombosis · Phase 4
- Volunteers · Phase 1
Mechanism of action
- ThrombinINHIBITOR
F2 inhibitor
Approval history
- approvedPriority reviewOct 19, 2010
Chemistry & pharmacology
Loading structure…
SMILES
CCCCCCOC(=O)NC(=N)c1ccc(NCc2nc3cc(C(=O)N(CCC(=O)OCC)c4ccccn4)ccc3n2C)cc1- Mol. weight
- 627.75 g/mol
- Lipinski Ro5
- 2 violation(s)
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
- Delivery
- Oral
- Availability
- Prescription Only
Oral
Yes
Parenteral
No
Topical
No
Black box warningProdrug
Sources
- ChEMBLCHEMBL539697 ↗
- WikipediaDabigatran ↗
- NCATSI0VM4M70GC ↗
- ChEMBLCHEMBL48361 ↗
- ChEMBLCHEMBL1615369 ↗
Also known as
- bibr 1048
- bibr 1048
- bibr 1048
- bibr 1048
- bibr 1048
- bibr 1048
- bibr 1048
- bibr-1048
- bibr-1048
- bibr-1048
- bibr-1048-bs-rs1
- bibr-1048-bs-rs1
- bibr 1048 ms
- bibr 1048 ms
- bibr-1048-ms
- bibr-1048-ms
- bibr-953
- bibr-953
- bibr 953 zw
- bibr 953 zw
- bibr-953-zw
- bibr-953-zw
- dabigatran
- dabigatran
- dabigatran
- dabigatran
- dabigatran
- dabigatran etexilate
- dabigatran etexilate
- dabigatran etexilate
- dabigatran etexilate
- dabigatran etexilate
- dabigatran etexilate
- dabigatran etexilate
- dabigatran etexilate mesilate
- dabigatran etexilate mesilate
- dabigatran etexilate mesylate
- dabigatran etexilate mesylate
- dabigatran etexilate mesylate
- dabigatran etexilate mesylate
- dabigatran etexilate methanesulfonate
- ethyl 3-[[[4-[[[(hexyloxyl)carbonyl]amino]iminomethyl]phenyl]amino]methyl]-1-methyl-1h-benzimidazol-5-yl]carbonyl](pyridin-2-yl)amino] propanoate
- ethyl 3-[[[4-[[[(hexyloxyl)carbonyl]amino]iminomethyl]phenyl]amino]methyl]-1-methyl-1h-benzimidazol-5-yl]carbonyl](pyridin-2-yl)amino] propanoate
- pradaxa
- pradaxa
- pradaxa
- pradaxa
- prazaxa
- prazaxa
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07190430 | Phase 1 | Oct 3, 2025 | Pfizer |
| NCT06945276 | Phase 1 | May 13, 2025 | National Institute of Allergy and Infectious Diseases (NIAID) |
| NCT06957366 | N/A | Apr 1, 2025 | McMaster University, University of Ottawa |
| NCT06818279 | Phase 2/Phase 3 (Phase 3) | Jan 31, 2025 | Institute of Liver and Biliary Sciences, India |
| NCT06791187 | Phase 1 | Jan 23, 2025 | Boehringer Ingelheim |
| NCT06650501 | Phase 4 | Jan 7, 2025 | McGill University, University of Melbourne |
| NCT06441916 | Phase 1 | Sep 25, 2024 | Mahidol University |
| NCT06504862 | Phase 1 | Aug 19, 2024 | Boehringer Ingelheim |
| NCT06551402 | Phase 3 | Aug 9, 2024 | Kafrelsheikh University |
| NCT06360055 | N/A | Apr 1, 2024 | Peking University |
| NCT06329895 | Phase 1 | Mar 25, 2024 | Bayer |
| NCT06212674 | N/A | Jan 31, 2024 | Medical University of Lodz, Pomeranian Medical University, Silesian University of Medicine |
| NCT05976685 | N/A | Jan 1, 2024 | University of Bern |
| NCT05955365 | Phase 3 | Sep 1, 2023 | University of Bern |
| NCT05959447 | Phase 1 | Aug 31, 2023 | GlaxoSmithKline |
| NCT05788328 | Phase 1 | Mar 27, 2023 | Pfizer |
| NCT06273215 | Phase 4 | Mar 5, 2023 | Peking University |
| NCT05673889 | Phase 1 | Jan 27, 2023 | Arvinas Inc, Pfizer |
| NCT05480475 | Phase 1 | Sep 3, 2022 | Idorsia Pharmaceuticals Ltd. |
| NCT05715658 | N/A | Aug 15, 2022 | Peking University |
Showing 20 of 225 trials
Page 1 / 12
Organizations
Research & Development (175)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Boehringer Ingelheim | For profit | 103 | 90 | 4 | 1998 |
| McMaster University | Academic/Hospital | 8 | 6 | 3 | 2005 |
| Pfizer | For profit | 7 | 6 | 2 | 2014 |
| Bayer | For profit | 4 | 3 | 2 | 2013 |
| Peking University | Academic/Hospital | 4 | 4 | 2 | 2022 |
| Eli Lilly | For profit | 3 | 2 | 1 | 2015 |
| Government of Canada | Government | 3 | 3 | 3 | 2009 |
| Hamilton Health Sciences Corporation | Academic/Hospital | 3 | 0 | 2 | 2019 |
| Johannes Gutenburg University | Academic/Hospital | 3 | 2 | 1 | 2014 |
| Nanjing Medical University | Academic/Hospital | 3 | 3 | 1 | 2016 |
| University of Bern | Academic/Hospital | 3 | 3 | 2 | 2017 |
| University of Paris | Academic/Hospital | 3 | 2 | 2 | 2007 |
| University of Sao Paulo | Academic/Hospital | 3 | 3 | 2 | 2014 |
| Vanderbilt University | Academic/Hospital | 3 | 2 | 2 | 2013 |
| Aalborg University | Academic/Hospital | 2 | 0 | 2 | 2018 |
| Aarhus University | Academic/Hospital | 2 | 1 | 1 | 2018 |
| AstraZeneca | For profit | 2 | 1 | 1 | 2015 |
| Capital Medical University | Academic/Hospital | 2 | 1 | 2 | 2017 |
| Danish Heart Foundation | Academic/Hospital | 2 | 2 | 1 | 2017 |
| Institute of Liver and Biliary Sciences, India | Academic/Hospital | 2 | 2 | 2 | 2020 |
175 organizations
Page 1 / 9
Marketing (18)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| Alembic | For profit | MKTG | Jul 7, 2017 |
| Alembic | For profit | SYN | Jun 14, 2024 |
| Alkem Labs Ltd | For profit | MKTG | Mar 11, 2020 |
| Apotex | For profit | MKTG | Dec 15, 2023 |
| Aurobindo Pharma | For profit | MKTG | May 14, 2025 |
| Boehringer Ingelheim | For profit | NDA2 | Oct 19, 2010 |
| Boehringer Ingelheim | For profit | NDA | Oct 19, 2010 |
| Dr. Reddy's Laboratories | For profit | MKTG | Oct 26, 2020 |
| Dr. Reddy's Laboratories | For profit | SYN | Jan 28, 2025 |
| Esteve Labs | For profit | MKTG | Mar 21, 2022 |
| Esteve Labs | For profit | SYN | Dec 19, 2024 |
| Glenmark Pharmaceuticals | For profit | MKTG | Apr 18, 2017 |
| Hetero Labs Ltd | For profit | MKTG | May 6, 2020 |
| MSN Laboratories | For profit | MKTG | Mar 21, 2022 |
| MSN Laboratories | For profit | SYN | May 22, 2024 |
| Mylan | For profit | MKTG | Jan 21, 2022 |
| Mylan | For profit | SYN | Feb 3, 2025 |
| Teva | For profit | MKTG | Apr 19, 2017 |